Literature DB >> 9140797

ACE, angiotensinogen and obesity: a potential pathway leading to hypertension.

R Cooper1, N McFarlane-Anderson, F I Bennett, R Wilks, A Puras, D Tewksbury, R Ward, T Forrester.   

Abstract

The renin-angiotensin system (RAS) plays a crucial role in the regulation of fluid volume, thereby influencing blood pressure (BP). Obesity is an important risk factor for hypertension, however the physiologic basis for this relationship has not been clarified. In a population survey we examined the potential relationship between the RAS and obesity. Based on community sampling, 449 individuals were recruited from metropolitan Kingston, Jamaica. Serum angiotensin-converting enzyme (ACE) and circulating angiotensinogen levels were measured and the associated genes were typed for previously described polymorphisms. Obese individuals (body mass index > 31) had significantly higher serum ACE and angiotensinogen levels, this relationship persisted for ACE in multivariate analyses controlling for BP, hypertension status, age, and gender. The insertion/deletion polymorphism of the ACE gene was associated with variation in the levels of ACE, but inconsistently with body mass index. Variants of the angiotensinogen gene leading to amino acid substitutions at positions 174 and 235 did not influence levels either of angiotensinogen or obesity. These data suggest that obesity may alter the levels of ACE and angiotensinogen, and provide a potential pathway through which obesity leads to elevation of BP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9140797     DOI: 10.1038/sj.jhh.1000391

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  50 in total

Review 1.  Obesity and hypertension.

Authors:  E Faloia; G Giacchetti; F Mantero
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 2.  New developments in mechanisms of obesity-induced hypertension: role of adipose tissue.

Authors:  A M Sharma; S Engeli; T Pischon
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 3.  Effect of exercise training on the renin-angiotensin-aldosterone system in healthy individuals: a systematic review and meta-analysis.

Authors:  Karla Goessler; Marcos Polito; Véronique Ann Cornelissen
Journal:  Hypertens Res       Date:  2015-09-24       Impact factor: 3.872

4.  The impact of laparoscopy on bariatric surgery.

Authors:  D R Cottam; N T Nguyen; G M Eid; P R Schauer
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

5.  Aliskiren combined with losartan: Thor's hammer or Sigurd's sword?

Authors:  Thomas R Lux; Heinrich Taegtmeyer
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

6.  Human adipose angiotensinogen gene expression and secretion are stimulated by cyclic AMP via increased DNA cyclic AMP responsive element binding activity.

Authors:  Valérie Serazin; Esther Dos Santos; Mireille Morot; Yves Giudicelli
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

Review 7.  Control of energy balance by the brain renin-angiotensin system.

Authors:  Kristin E Claflin; Justin L Grobe
Journal:  Curr Hypertens Rep       Date:  2015-05       Impact factor: 5.369

8.  Blood pressure control and weight loss in overweight or obese patients with previously treated or untreated mild to moderate hypertension given valsartan: An open-label study comparing pretreatment and posttreatment values.

Authors:  Aldo S Villecco; Cinzia Cocci; Maurizio Di Emidio
Journal:  Curr Ther Res Clin Exp       Date:  2004-03

9.  Prolonged treatment with angiotensin 1-7 improves endothelial function in diet-induced obesity.

Authors:  Andreas M Beyer; Deng-Fu Guo; Kamal Rahmouni
Journal:  J Hypertens       Date:  2013-04       Impact factor: 4.844

Review 10.  Opposing tissue-specific roles of angiotensin in the pathogenesis of obesity, and implications for obesity-related hypertension.

Authors:  Nicole K Littlejohn; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-21       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.